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Abstract With a view to developing therapeutic strategies
against hepatocellular carcinoma (HCC), we have recently
shown that co-expression of c-myc and the X protein of hepatitis
B virus (HBx) resulted in the development of HCC in the X-myc
transgenic mice [Lakhtakia et al., J. Gastroenterol. Hepatol. 18
(2003) 80^91]. We now show in cell culture-based studies that
small interfering RNA (siRNA) corresponding to HBx and c-
myc can regulate expression and transactivation of the target
genes. Expression vectors for small hairpin RNAs (shRNAs)
against two di¡erent regions each of the HBx and c-myc open
reading frames were constructed and their regulatory e¡ects
were investigated in COS-1 cells. A dose-dependent speci¢c in-
hibition in the expression levels of HBx and c-myc was observed
with individual shRNAs. Further, the recombinantly expressed
shRNAs also blocked the transactivation functions of their cog-
nate genes. Though each shRNA worked at a di¡erent e⁄-
ciency, the inhibitory e¡ects with two di¡erent shRNAs were
cumulative. These results appear promising for developing a
siRNA-based therapy for HCC.
9 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
RNA interference (RNAi) is a ubiquitous mechanism of
gene regulation in a wide variety of organisms, including ani-
mals, plants, fungi and protists, that mediates resistance to
both endogenous parasitic and exogenous pathogenic nucleic
acids [1,2]. It also appears to play a key role in cellular pro-
gramming of gene expression and development [3]. The pro-
cess of RNAi involves generation of 21^23-nt double-stranded
RNA (dsRNA) termed small interfering RNA (siRNA) and
subsequent degradation of target mRNAs (reviewed in [4]).
The siRNAs are associated with regulating the levels of pro-
teins. The dsRNA molecules are cleaved by the RNase III-like
enzyme ‘Dicer’ to generate siRNAs that in turn direct the
recognition and degradation of homologous mRNAs by a
multiprotein complex called RNA-induced silencing complex
[5]. Direct introduction of dsRNA into mammalian cells may
not produce Dicer-mediated siRNAs as e⁄ciently as in insect
cells and therefore may fail to induce RNAi [6]. Nevertheless,
the requirement for Dicer in generation of siRNAs can be
experimentally bypassed using either synthetic 21-nucleotide
siRNA duplexes [7] or small hairpin RNAs (shRNA) tran-
scribed in vitro or in vivo from DNA templates [8,9]. Such
siRNAs have been shown to inhibit expression of transfected
as well as endogenous genes in several mammalian cells [10].
As siRNAs can trigger sequence-speci¢c RNAi in cells, it has
generated considerable interest in annotating the function of
genes in di¡erent living systems without actually destroying or
mutating the genetic material [11^13]. Besides, RNAi seems to
hold promise for treating many infectious diseases and cancers
including hepatocellular carcinoma (HCC) [14^17].
Recently, we have developed a transgenic mouse model of
HCC using a bicistronic recombinant X-myc [18]. Co-expres-
sion of c-myc and the X protein of hepatitis B virus (HBx)
resulted in the development of liver-speci¢c tumors in the X-
myc mice [19,20]. To develop a therapeutic strategy for liver
cancer based on gene silencing, we have studied the e¡ect of
siRNAs on the expression of cognate genes and their trans-
activation functions in cell culture. Our results with siRNAs
against two di¡erent regions of HBx and c-myc show that the
gene silencing was highly speci¢c for its target. We have also
observed additive siRNA e¡ects when more than one shRNA
corresponding to di¡erent regions of the same gene was used
in the experiment.
2. Materials and methods
2.1. siRNA expression vectors
Signature siRNA sequences corresponding to two di¡erent func-
tional domains of HBx (X-D and X-E) and the mouse c-myc (M-T
and M-Z) were selected for the chemical synthesis of oligonucleotides
(Sigma Genosys, USA). The 5P ends of these oligonucleotides were
phosphorylated by T4 polynucleotide kinase, annealed in pairs and
cloned directly into the pSilencer 1.0-U6 expression vector (Ambion,
USA).
Expression vectors for the native HBx (X0) have been described
[21]. The mouse c-myc expression vector (pSG5-myc) was constructed
by amplifying the 1.3-kb open reading frame region using reverse
transcription polymerase chain reaction and cloning into the pSG5
expression vector (Stratagene, USA) as an EcoRI fragment. Details
of the RSV-CAT reporter construct having the long terminal repeat of
Rous sarcoma virus (3500 to +51) can be found elsewhere [22].
2.2. Cell culture, DNA transfection and immunoprecipitation
COS-1 cells (ATCC 1650) in 60-mm culture dishes were transiently
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transfected with 1 Wg of either HBx or c-myc expression vectors using
Lipofectin (Gibco-BRL, USA). In parallel, the cells were co-trans-
fected with increasing amounts (0.5, 1 and 2 Wg) of the siRNA
expression plasmids X-D or X-E (for HBx), and M-T or M-Z (for
c-myc). After 48 h, the cells were harvested in sodium dodecyl sulfate
(SDS) bu¡er (62.5 mM Tris^HCl, pH 6.8, 2% w/w SDS, 10% glycerol,
50 mM dithiothreitol and 0.01% bromophenol blue) and the proteins
were resolved in a 15% SDS^polyacrylamide gel electrophoresis. After
transfer to Hybond ECL nitrocellulose membrane, the blot was ¢rst
incubated with speci¢c monoclonal antibodies for HBx [21] or c-myc
(Santa Cruz, USA) followed by incubation with the horseradish per-
oxidase-conjugated secondary antibody. The protein bands were de-
tected using LumiGLO chemiluminescent reagent (Cell Signaling
Technology, USA). Fold expression was estimated by densitometric
analysis of the autoradiograms using Kodak digital science 1D (ver.
1.6). The levels of signi¢cance were calculated by Student’s t-test.
2.3. RNA isolation and Northern blot assay
Total RNA was isolated form the transfected COS-1 cells using
TRIzol reagent as per the supplier’s instructions (Gibco BRL,
USA). The samples (20 Wg) were resolved in a formaldehyde/agarose
gel (1%) and Northern hybridization was performed using 32P-labeled
HBx or c-myc probes [23]. Fold inhibition in the expression of RNA
was determined by densitometric analysis.
2.4. Chloramphenicol acetyltransferase (CAT) assay
COS-1 cells were transiently transfected with the RSV-CAT report-
er construct (0.5 Wg) and the expression plasmids for either HBx or
c-myc (1 Wg each) as above. For the transactivation inhibition studies,
the cells were also co-transfected with increasing amounts (0.5, 1 and
2 Wg) of the shRNA expression vectors. After 48 h, the cells were
harvested and assayed for CAT activity [22]. Fold CAT inhibition
was estimated by densitometric analysis as above and the levels of
signi¢cance were calculated by Student’s t-test.
3. Results
3.1. siRNA design and expression vectors
siRNAs for HBx and mouse c-myc were designed using
Jack Lin’s siRNA sequence ¢nder (http://www.ic.sunysb.edu/
Stu/shilin/rnai.html) or Qiagen’s design by sequence (http://
python.penguindreams.net/Xeragon_Order_Entry/jsp/Search-
BySequence.jsp). Though several putative sites for siRNA
were predicted across the length of both HBx and c-myc, we
selected two regions of molecule that encode important func-
tional regions. Fig. 1 shows the scheme of domain structures
of HBx and c-myc, location of the siRNA sites and oligonu-
cleotide sequences of the shRNA inserts. For HBx (Fig. 1A),
regions D and E play important roles in signal transduction
and transactivation [24,25] and therefore, the shRNAs di-
rected against these regions were termed X-D and X-E respec-
tively. The shRNA constructs directed against the transacti-
vation and leucine zipper domains of c-myc [26] were called
M-T and M-Z respectively. The lengths of all the sense and
antisense deoxyribo-oligonucleotides were 53 and 61 nucleo-
Fig. 1. Design and DNA sequence of the oligonucleotides for the expression of shRNA against HBx and c-myc. A: Domain structure of HBx
(A through F), location and sequence of shRNA for domains D (X-D) and E (X-E). B: Schematic organization of c-myc showing transactiva-
tion (TAD) and leucine zipper (LZ) domains, sequences of shRNA speci¢c for TAD (M-T) and LZ domains (M-Z) with their location.
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tides respectively. Each oligonucleotide had a small sense,
loop and an antisense region so as to express siRNA as a
stable hairpin structure [27]. The four sets of shRNA oligo-
nucleotides were cloned between the ApaI and EcoRI sites of
the pSilencer 1.0-U6 plasmid (Ambion) to put them under the
transcriptional control of the U6 RNA polymerase III pro-
moter. The dideoxy chain termination method was used to
con¢rm the sequence of each construct.
3.2. Speci¢c inhibition of protein and RNA levels by shRNAs
To investigate the inhibitory action of siRNAs on the levels
of target proteins, the expression vectors for HBx and mouse
c-myc were transfected in COS-1 cells along with increasing
amounts of the shRNA plasmids and analyzed by immuno-
precipitation. As shown in Fig. 2A, the level of HBx was
speci¢cally inhibited by both X-D (lanes 3^5) and X-E
shRNA (lanes 6^8). Though X-D was relatively more e⁄cient
than X-E in inhibiting the HBx levels, the e¡ect was cumu-
lative in the presence of the two shRNAs (lanes 9^11). The
inhibition levels ranged between 1.5- and 3-fold with individ-
ual shRNAs. However, the inhibition (V5-fold) was signi¢-
cantly higher (P6 0.003) in the presence of both X-D and
X-E. The inhibitory e¡ect was speci¢c for HBx as no inter-
ference was observed with the myc-speci¢c shRNAs M-T and
M-Z (lanes 12^14).
Like HBx, both shRNAs against c-myc were also e¡ective
against the target gene (Fig. 2B). M-T (lanes 3^5) was more
e¡ective than M-Z (lanes 6^8) and showed a 5^10-fold inhi-
bition in the expression of c-myc. Maximum inhibition was
only two-fold at the highest concentration (2 Wg) of M-Z (lane
8). The interference was cumulative and the expression of
target protein was virtually abolished (P6 0.008) in the pres-
ence of both M-T and M-Z (lanes 9^11). Further, no inter-
ference in the c-myc levels was observed in the presence of
HBx-speci¢c X-D and X-E (lanes 12^14) showing their spec-
i¢city for the respective target genes.
To con¢rm whether the decreased protein levels of HBx and
c-myc were due to down-regulation of the respective mRNA
levels by shRNAs, Northern blot assay was done using total
RNA from the transfected cells. As observed with the X pro-
tein, a two- to three-fold decrease in the mRNA levels was
also observed in the presence of X-D and/or X-E (Fig. 2C).
The RNA level was e¡ectively lowered by nearly three-fold in
the presence of either X-D or X-E (lanes 2 and 3). The inhi-
bition was cumulative as the RNA levels dropped toV8-fold
in the presence of both X-D and X-E (lane 4). Similarly, the
myc mRNA levels were also inhibited in the presence of M-T
or M-Z (data not shown). Further, accumulation of 21^22-
nucleotide RNA species was also observed in the presence of
all four shRNAs (data not shown).
3.3. Regulation of transactivation function by shRNAs
To demonstrate that inhibition of target gene expression
was not a direct e¡ect of RNA^protein interaction but rather
an e¡ect of the decreased level of the protein, the transactiva-
tion property of HBx and c-myc was studied in transient
transfection assays using the RSV-CAT reporter gene con-
struct. As shown in Fig. 3A, the HBx-mediated transactiva-
tion of the RSV long terminal repeat could be inhibited in the
presence of both X-D (lanes 2^4) and X-E (lanes 5^7). As
observed earlier, X-D was relatively more e⁄cient than X-E
in inhibiting the transactivation function of HBx. Further, the
e¡ect was cumulative in the presence of the two shRNAs
(lanes 8^10) and the transactivation level could be reduced
to an undetectable level (lane 10).
Like HBx, the transactivator function of c-myc could also
be inhibited by the two shRNAs (Fig. 3B). M-T (lanes 2^4)
appeared relatively more e⁄cient than M-Z (lanes 5^7) and at
a 1:1 molar ratio, no CAT activity could be detected (lanes 3
and 4). The inhibitory e¡ect was cumulative in the presence of
both M-T and M-Z (lanes 8^10) and the transactivation level
could be inhibited to an undetectable level (lanes 9 and 10).
Fig. 2. Inhibition of the expression of HBx and c-myc by shRNAs. For monitoring the protein levels, COS-1 cells were co-transfected with ex-
pression plasmids (0.5 Wg) for HBx (A) or c-myc (B) along with increasing amounts (0.5, 1 and 2 Wg) of di¡erent shRNA constructs. After
48 h, the cell extracts were immunoprecipitated and bands were detected by chemiluminescence. For measuring the mRNA levels (C), cells
were co-transfected with HBx (0.5 Wg) and the shRNA expression vectors X-D and/or X-E (2 Wg each) as indicated. Total RNA was extracted
and the expression level was measured by Northern blot assay using 32P-labeled HBx probe. Top bars show immunoprecipitated protein bands
(A,B) or RNA bands (C). Densitometric scan was used to give the histograms shown below. Loading control for RNA (18S RNA) is shown at
the bottom of C.
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As expected, X-D and X-E did not inhibit the myc-dependent
transactivation, while M-T and M-Z did not interfere with
HBx-dependent activity (data not shown).
4. Discussion
Gene expression can be regulated at the post-transcriptional
level using a wide range of approaches including antisense
RNA, ribozymes and RNA interference. Extensive work has
been done to validate the e¡ectiveness of these strategies in
cell culture, animal models as well as in limited clinical trials
[28^30]. From these studies, it is now clear that the RNAi
approach is far more e⁄cient than the antisense RNA and
ribozyme strategies [31^33]. The ability to selectively silence
mammalian gene expression using siRNA has not only
opened new and exciting routes to understand mammalian
cell biology in health and disease, but has also given us the
ability to selectively regulate the expression of genes that may
have detrimental e¡ect(s) on cells including their uncontrolled
proliferation. Besides, this has also provided a powerful tool
to silence the genes of pathogenic viruses, bacteria, fungi and
other agents that may be crucial for survival and/or disease
development. More recently, the e¡ectiveness of siRNA has
been experimentally demonstrated against some pathogenic
viruses such as human immunode¢ciency virus-1 [34^36], hep-
atitis B virus [37,38], hepatitis C virus [39,40], poliovirus [41],
rotavirus [42], human papillomavirus [43], Rous sarcoma virus
[44], and Q-herpesvirus [45]. Besides, siRNA has also been
found e¡ective against trypanosomes [46], plasmodium [47],
Fas-mediated fulminant hepatitis in mice [48], cancer growth
(HCC) by inhibiting cyclin E overexpression [17], and prion
protein accumulation in neuroblastoma cells [49]. Thus, si-
RNA has tremendous promise as a therapeutic tool for tar-
geted gene silencing. However, its utility will depend on its
speci¢city, i.e. ability to speci¢cally knock down the target
gene without interference with the expression or function of
other genes or proteins.
With the ultimate aim of developing gene therapy for HCC,
we have evaluated the e¡ectiveness of shRNAs on the post-
transcriptional regulation of two di¡erent transactivator genes
^ the viral transactivator HBx and the cellular transcription
factor c-myc. While c-myc is known to play a major role in
cellular growth and di¡erentiation [50], HBx is essential for
viral replication and development of hepatocellular carcinoma
[51,52]. Our results from the mammalian cell culture show the
e¡ectiveness of the siRNA approach in the regulation of the
intracellular levels of HBx and c-myc. The e¡ect of the
shRNAs used in the present study was highly speci¢c as no
cross-interference was observed. Further, the cumulative in-
hibitory e¡ect of multiple siRNAs against one target gene is
likely to be more successful due to the ampli¢cation of the
RNA-induced silencing complex. The observed di¡erences in
the potency of siRNAs targeted to di¡erent regions of the
same mRNA suggest that target accessibility is an important
factor governing the siRNA response. Altogether, these re-
sults are encouraging since they suggest that siRNA-based
therapeutic agents are likely to have inherent molecular spec-
i¢city. Though exquisite sequence speci¢city for the target
mRNAs has been questioned recently [53,54] and the activa-
tion of interferon responses has also been observed in the
presence of siRNAs [55,56], our results on shRNAs for HBx
and c-myc provide a case-speci¢c example of transcription
factors that are known to co-operate in order to induce
HCC in the X-myc transgenic mouse model [18]. It may be
noted that a functional interaction between HBx and c-myc
appears to be essential for the development of HCC in X-myc
mice [19] and an analogous situation may be associated with
the development of HCC in humans [57]. Thus, our results on
the regulation of HBx and c-myc by siRNA are encouraging
for developing and testing siRNA-based therapeutic agents
for HCC.
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